SIGA Technologies, Inc.
Budget
€100 — €0
EP Access
0
accredited persons
Staff
2
1 FTE
EU Grants
None
Mission & Goals
SIGA is a biopharmaceutical company whose objective is to develop medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We partner with, which includes obtaining funding and selling our products, governments, foundations, and other organizations that share the responsibility for global health security.
EU Legislative Interests
(1) Strategy to support medical countermeasures against public health threats (2) New EU Stockpiling Strategy (3) EU’s next long-term budget (MFF) – EU funding for civil protection, preparedness and response to crises
Communication Activities
SIGA would like to respond to the above calls for evidence and consultations through in-person meetings, written correspondence, and publications.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EUCOPE, https://www.eucope.org/ BIO, https://www.bio.org/
Commissioner Meetings
No recorded meetings with EU commissioners.